Genes, kits, screening methods and applications targeting novel coronavirus spikes

Technology of a coronavirus, screening method, applied in the field of genetic engineering

Active Publication Date: 2022-04-08
GENERAL HOSPITAL OF TIANJIN MEDICAL UNIV
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0017] In order to solve the problem that the existing drugs cannot specifically target the spine (S), the key structure of SARS-CoV-2, the present invention combines bioinformatics methods and RNA editing technology based on the CRISPR-Cas13a system, and proposes a CRISPR-Cas13a-based The technology of Cas13a system to recognize and degrade SARS-CoV-2 S in human cells

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Genes, kits, screening methods and applications targeting novel coronavirus spikes
  • Genes, kits, screening methods and applications targeting novel coronavirus spikes
  • Genes, kits, screening methods and applications targeting novel coronavirus spikes

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0082] 1. Search for specific fragments of SARS-CoV-2 S: using comprehensive methods such as sequence alignment, three-dimensional structure superposition analysis, and molecular docking simulation. Such as figure 1 The provided amino acid sequence alignment and three-dimensional structure overlay alignment of the receptor binding domain (RBD) of SARS-CoV-2 S and SARS-CoV S.

[0083] (1) Sequence alignment: from NCBI database ( https: / / www.ncbi.nlm.nih.gov / ) for SARS-CoV-2 S, gene sequences of SARS-CoV S and MERS-CoV S. The sequence numbers of SARS-CoV-2 S, SARS-CoV S and MERS-CoV S are MN908947.3, AY278488.2 and KF600652.1, respectively. S-protein sequence alignment and visualization was performed using Clustal w2.1 and Exprint 2.0.

[0084] According to the sequence alignment results, the receptor-binding domain (Receptor-Binding-Domain, RBM) of the SARS-CoV-2 S protein has two residues that are significantly different from the residues of the corresponding fragment of t...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a gene, a kit, a screening method and an application targeting novel coronavirus spines, and relates to the technical field of genetic engineering. The RNA sequence of the gene targeting the spike of the novel coronavirus SARS‑CoV‑2 is SEQ ID NO:6. Specific therapeutic kits against SARS-CoV-2 infection comprising said genes. The present invention screens out the crRNA sequence with the highest S degrading efficiency, so as to effectively reduce the intracellular viral load. The present invention skillfully combines bioinformatics simulation and biological experiments, and the targetedly designed CRISPR-Cas13a system can specifically recognize and degrade S RNA in human alveolar epithelial cells. The crRNA designed by the present invention is expected to be applied in the development of specific therapeutic tools and drugs against SARS-CoV-2 infection.

Description

technical field [0001] The invention belongs to the technical field of genetic engineering, and in particular relates to a gene targeting novel coronavirus spines, a kit, a screening method and an application. Background technique [0002] Currently, the novel coronavirus SARS-CoV-2 has caused the global pandemic of coronavirus pneumonia (COVID-19), but there is currently no specific therapeutic drug against SARS-CoV-2. [0003] Although antiviral drugs such as lopinavir, ritonavir, remdesivir and chloroquine have shown inhibitory activity against SARS-CoV or SARS-CoV-2 in vitro, the clinical outcomes of these drugs in patients with COVID-19 No apparent benefit. [0004] However, clinical evidence does not recommend the use of corticosteroids for treatment because of its limited benefit and serious complications. Convalescent plasma or immune globulin has potential therapeutic capabilities, but its safety and efficacy still need to be verified by large-scale clinical trial...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): C12N15/50C12N15/867C12N9/22C12N15/113C07K14/165C40B40/06C40B50/06A61K31/7088A61P31/14
CPCC07K14/005C12N9/22C12N15/86C12N15/113C40B40/06C40B50/06A61K31/7088A61P31/14C12N2310/20C12N2740/15043C12N2770/20022
Inventor 康春生王琳周俊虎王琦雪王蕴非
Owner GENERAL HOSPITAL OF TIANJIN MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap